Table 2.
Cost-effectiveness analysis results for pneumococcal vaccination strategies in 65-year-olds by race
| Cost | Incremental cost | Effectiveness (QALY) | Incremental effectiveness (QALY) | ICER (per QALY gained) | |
|---|---|---|---|---|---|
| Base case vaccine effectiveness | |||||
| Black population | |||||
| No vaccination | $427 | – | 7.87998 | – | – |
| PCV20 | $551 | $124 | 7.88072 | 0.00073 | $169,540 |
| PCV15 and PPSV23 | $622 | $70 | 7.88085 | 0.00013 | $535,797 |
| Non-Black population | |||||
| No vaccination | $342 | – | 8.49604 | – | – |
| PCV20 | $493 | $151 | 8.49676 | 0.00072 | $210,529 |
| PCV15 and PPSV23 | $576 | $83 | 8.49688 | 0.00011 | $728,423 |
| CDC vaccine effectiveness | |||||
| Black population | |||||
| No vaccination | $342 | – | 8.49604 | – | – |
| PCV20 | $494 | $152 | 8.49674 | 0.00069 | $219,611 |
| PCV15 and PPSV23 | $578 | $84 | 8.49679 | 0.00005 | $1,667,248 |
| Non-Black population | |||||
| No vaccination | $427 | – | 7.87998 | – | – |
| PCV20 | $552 | $125 | 7.88069 | 0.00071 | $177,104 |
| PCV15 and PPSV23 | $624 | $72 | 7.88074 | 0.00005 | $1,406,539 |
ICER incremental cost-effectiveness ratio, PCV15 15-valent pneumococcal conjugate vaccine, PCV20 20-valent pneumococcal conjugate vaccine, PPSV23 23-valent pneumococcal polysaccharide vaccine, QALY quality-adjusted life years